Oncotelic issues $335K convertible note to Blue Lake Partners as part of $1M financing

Oncotelic Therapeutics, Inc.

Issued $335,000 convertible promissory note to Blue Lake Partners, LLC at 12% interest.
Note matures in one year; convertible into common stock at $0.10 per share.
Issued 3,025,000 warrants to purchase common stock at $0.20 per share.
Financing part of cumulative $1M raise via JH Darbie; $605K from Mast Hill in May 2022.
Proceeds for general working capital; not for insider loans or illegal purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.